We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

84 hedge funds and large institutions have $191M invested in Eiger BioPharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 20 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 9

50% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 20

8% more funds holding

Funds holding: 78 → 84 (+6)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

13% less capital invested

Capital invested by funds: $220M → $191M (-$28.2M)

Holders
84
Holders Change
+6
Holders Change %
+7.69%
% of All Funds
1.84%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
15
Increased
30
Reduced
20
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$2.99M
2
Northern Trust
Northern Trust
Illinois
+$2.27M
3
CS
Credit Suisse
Switzerland
+$1.47M
4
Citadel Advisors
Citadel Advisors
Florida
+$1.42M
5
FCM
Farallon Capital Management
California
+$1.35M

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$19M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$4.71M
3
BC
Broadfin Capital
New York
-$3.13M
4
TI
Telemetry Investments
New York
-$1.72M
5
CAM
Cormorant Asset Management
Massachusetts
-$1.65M
Name Holding Trade Value Shares
Change 		Change in
Stake
DS
26
DRW Securities
Illinois
$1.13M +$437K +1,346 +58%
Goldman Sachs
27
Goldman Sachs
New York
$1.04M +$741K +2,282 +210%
BCM
28
Bridgeway Capital Management
Texas
$958K – – –
TMC
29
Trellus Management Company
Florida
$871K +$172K +530 +23%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$761K +$15.6K +48 +2%
EP
31
Eversept Partners
New York
$715K – – –
CC
32
Caxton Corporation
New Jersey
$636K +$1.3K +4 +0.2%
DCM
33
Driehaus Capital Management
Illinois
$615K – – –
N
34
Nuveen
North Carolina
$611K -$405K -1,247 -39%
Charles Schwab
35
Charles Schwab
California
$547K – – –
UOC
36
UBS O'Connor
Illinois
$527K +$556K +1,713 New
AG
37
Algert Global
California
$481K +$197K +605 +63%
TAM
38
Tocqueville Asset Management
New York
$371K +$20.8K +64 +6%
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$370K – – –
State of Wisconsin Investment Board
40
State of Wisconsin Investment Board
Wisconsin
$361K +$381K +1,173 New
Bank of America
41
Bank of America
North Carolina
$312K +$38K +117 +13%
SMH
42
Sanders Morris Harris
Texas
$302K – – –
OAM
43
Oxford Asset Management
United Kingdom
$283K +$88.4K +272 +42%
WG
44
Winton Group
United Kingdom
$271K +$286K +880 New
Two Sigma Investments
45
Two Sigma Investments
New York
$257K -$567K -1,744 -68%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$246K – – –
Los Angeles Capital Management
47
Los Angeles Capital Management
California
$242K +$140K +432 +121%
Jacobs Levy Equity Management
48
Jacobs Levy Equity Management
New Jersey
$222K +$235K +722 New
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$221K +$5.85K +18 +3%
Wells Fargo
50
Wells Fargo
California
$214K +$207K +638 +1,081%
1
2
3 4

EIGR Hedge Fund Activity: Q3 2019 in Review

84 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2019, worth a combined $191M — down 13% from $220M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new EIGR positions and 9 closed out — a net gain of 6 holders — while 30 added to existing stakes and 20 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $2.99M. The largest seller was Vivo Capital, exiting entirely with an estimated $19M sold.

  • 84 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2019, up from 78 in Q2 2019.
  • Funds reported $191M of Eiger BioPharmaceuticals, Inc. stock for Q3 2019, down 13% quarter-over-quarter.
  • 15 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2019 and 9 closed out, a net change of +6 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2019 was JP Morgan Chase, an estimated $2.99M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2019 was Vivo Capital, an estimated $19M sold.

Based on aggregated 13F filings for Q3 2019.